The evolution of coagulation and fibrinolysis has not been thoroughly evaluated in allogeneic SCT. In this pilot study, we characterized the adaptive mechanisms of coagulation and fibrinolysis during allogeneic SCT and 3-month followup and studied possible associations with outcome, including acute GVHD. Thirty patients underwent SCT for a haematological malignancy after myeloablative conditioning. Nineteen patients received the transplant from an HLAidentical sibling and 11 from an unrelated donor. GVHD prophylaxis consisted of CYA and MTX, with methylprednisolone in sibling transplants. Serial coagulation and fibrinolytic activity markers were assessed, including prothrombin fragments 1 þ 2 (F1 þ 2), thrombin time, D-dimer, tissue-type plasminogen-activator (tPA) and plasminogenactivator inhibitor (PAI-1). Early during conditioning therapy, F1 þ 2 and D-dimer increased threefold indicating thrombin generation and fibrin turnover. TPA activity peaked before engraftment, concurring with diminished PAI-1. At 10 days after transplantation shortened thrombin time (o15 s), F1 þ 2 exceeding 0.7 nmol/L and PAI-1 3.0 IU/mL were associated with the development of GVHD. In conclusion, early maladaptation, that is, upregulated thrombin generation and inhibition of fibrinolysis, occurred in one-third of the SCT patients associating with the development of GVHD, a finding suggesting an interplay between coagulation and immunology during SCT.
Introduction
Allogeneic haematopoietic SCT is an established method for the treatment of haematological malignancies, but morbidity and mortality are still major problems. Acute complications include GVHD, haematopoietic SCT-associated microangiopathy, [1] [2] [3] veno-occlusive disease 4 and capillary leakage syndrome. 5 These complications associate with endothelial injury 6, 7 preceded by increased plasma TNFa levels. 8 Even elevated numbers of circulating endothelial cells may contribute. 9 However, endothelial markers are unspecific and confounded by several factors. Plt activation is also characteristic for generalized endothelial injury, exposing phospholipid surfaces to generate thrombin, and secrete inflammatory mediators, also after SCT. [10] [11] [12] Some studies have focused on coagulation and fibrinolytic activities during SCT. In a study of mainly autologous transplant patients, increased coagulation activity was reported during conditioning therapy, whereas fibrinolytic mechanisms were shown to be triggered later. 13 Studies with allogeneic patients are scarce. Earlier reports have included heterogenic patient groups and conditioning therapies, as well as a limited follow-up and set of markers for analysis of coagulation and fibrinolysis. The main focus has been on the development of complications, such as veno-occlusive disease, without the knowledge of natural evolution of coagulation and fibrinolysis after SCT. [14] [15] [16] The aim of our pilot study was to characterize the natural evolution of coagulation and fibrinolysis activities in connection with SCT. We analysed different clinical factors affecting these mechanisms, including disease status at the time of transplantation, donor type and source of the graft. As endothelial damage has been reported to precede the complications of SCT, we wanted to evaluate the possible associating role of coagulation and fibrinolysis. In particular, we explored the possible associations of these activities with the development of GVHD and with non-relapse mortality.
Patients and methods

Study population
Thirty consecutive patients undergoing myeloablative allogeneic SCT for a haematological malignancy between January 2004 and May 2005 consented to take part in this prospective study lasting 3 months with repetitive laboratory monitoring. The median clinical follow-up time for the living patients was 40 months (range 32-46 months). The inclusion criteria were age over 18 years and myeloablative conditioning therapy with CY and TBI. The exclusion criteria were preceding thrombosis during the past 3 months and/or anticoagulant therapy. The diagnoses and characteristics of the patients are shown in Table 1 . Nineteen patients underwent allogeneic SCT from an HLA-identical sibling and 11 patients from an unrelated donor. The stem cells were harvested from BM in 21 cases and from peripheral blood in nine cases. Disease status at the time of transplantation was considered low risk when the patient had either CML in the first chronic phase or acute leukaemia in first remission. All other haematological diseases were considered high risk. The general policy in our unit was to use BM as the source of graft in low-risk patients, whereas peripheral blood was preferred for highrisk patients. To assess the effect of age, patients were divided into two age groups, with 40 years as a cutoff. The study was approved by the Ethics Committee of the Helsinki University Central Hospital, and written informed consent was obtained from each patient.
Treatment regimens
The myeloablative-conditioning regimen consisted of CY 60 mg/kg once daily i.v. on days À6 and À5 (total dose 120 mg/kg) and TBI of 12.0 Gy in six fractions of 2.0 Gy (on days À4 to 0), with the lungs receiving only 10.0 Gy. Infusion of the graft was performed on day 0. GVHD prophylaxis consisted of CYA and a short course of MTX (15 mg/m 2 on day þ 1, 10 mg/m 2 on days þ 3 and þ 6). CYA was started on day À1 for unrelated and on day À3 for sibling transplants. The target concentration of CYA was 400 mg/L during the first 2 weeks and 200-300 mg/L subsequently in unrelated and 100-200 mg/L in sibling transplants up to 3 months. CYA was administered for a total of 9 months and then tapered off over a 6-week period. If the donor was unrelated, antithymocyte globulin (ATG; Thymoglobuline; Sangstat, Lyon, France) 2 mg/kg/ day was given on days À3 to À1. Patients undergoing transplantation from a sibling donor received methylprednisolone (MP) from day þ 8 onwards as GVHD prophylaxis. The maximum MP dose was 1 mg/kg, and the drug was tapered off by day þ 110, as described earlier. 17 Grafts were non-manipulated except for removal of red cells and plasma from the BM grafts in case of ABO incompatibility.
Acute GVHD was assessed and graded according to published criteria 18 and treated with MP (2)À10 mg/kg/d divided into four i.v. doses at the time of its appearance. If the response was prompt, the MP dose was reduced to 2 mg/kg/d after 3 days; otherwise, the dose was halved every 3 days for three times and thereafter according to the clinical situation.
Blood collection and analysis of the samples Blood samples were collected before the transplantation (day À10), during conditioning therapy (day À2), early after transplantation (day þ 10), after engraftment (day þ 24) and at the end of the study (day þ 90). These time points are referred to as indicated above throughout the text. The blood samples were obtained in the morning during the transplantation period and always before possible blood transfusions. Samples for coagulation assays were collected in 109 mM (3.2%) trisodium citrate from the antecubital veins using brief stasis only. The samples were immediately transferred to the laboratory and plasma was separated by centrifugation for 15 min at 2000 g at room temperature. Plasma was frozen in aliquots at À70 1C until assayed, if not tested immediately. Blood for plasminogenactivator inhibitor type 1 activity (PAI-1) and tissue-type plasminogen activator (tPA Ag and Activity, Act) was collected in vacuum tubes containing 0.5 M acidic (pH 4.3) citrate buffer, to inhibit the in vitro complex formation and plt activation (Biopool Stabilyte tubes Trinity Biotech, Bray, Ireland), as described. tPA Act, 20 using the two-chain tPA to develop a standard curve. TPA Ag was assayed using Biopool TintElize tPA (Trinity Biotech). The reference values for tPA Act and Ag were 0.2-2.0 IU/mL and 1-20 ng/mL, respectively. To verify the performance and accuracy of the tPA and PAI-1 assays, fibrinolysis reference plasma (Trinity Biotech) was added to each run.
Thrombophilia screening consisted of factor V Leiden (FVR506Q) and prothrombin G20210A gene mutations, activated protein C resistance and antiphospholipid antibodies (against 2 glycoprotein I and cardiolipin) and lupus anticoagulant. FV Leiden and the prothrombin gene mutations were identified with an automatic PCR-based solid minisequencing method and primers. APC resistance was determined with a functional APTT-based method with predilution of patient plasma with FV-depleted plasma (Coatest APC Resistance V, Chromogenix, Lexington, MA, USA). Anticardiolipin and anti 2-glycoprotein IgG antibodies were assessed with enzyme immunoassays (Phadia GmbH, Freiburg, Germany). Lupus anticoagulant was screened by means of APTT (IL Test APTT SP-reagent, Instrumentation Laboratory, Lexington, MA, USA) and dRVTT (dilute Russell's Viper Venom test, American Diagnostica, Pfungstadt, Germany) assays supplemented with a mixing study, if needed.
Statistical analysis
Statistical calculations were performed using SPSS for Windows version 15.0 (SPSS, Chicago, IL, USA). Nonnormally distributed data were expressed as median and percentiles (25th and 75th). Two-tailed P-values o0.05 were considered statistically significant. Changes in variables were evaluated with Friedman's test and Dunn's multiple comparison test. Different change patterns in the variables between the two groups during the study were compared with analysis of variance (ANOVA) with repeated measures. The Mann-Whitney U-test was used for comparisons of the differences in the variables between the two groups at single time points without correcting the P-values. Spearman's rank correlation coefficients were calculated to test the correlations between the variables. Fisher's exact test and a logistic regression model defined the levels of variables that would associate with acute GVHD and non-relapse mortality. The cutoff values for different variables were data driven. On the rare case of missing values, all results were checked by imputation with curve fitting.
Results
Thrombin generation and fibrin turnover
To assess the evolution of coagulation and fibrinolytic activity, we measured prothrombin fragments F1 þ 2, Ddimer, thrombin time and fibrinogen. As a sign of thrombin generation, F1 þ 2 levels increased nearly threefold already during conditioning therapy. These values remained twofold higher than at the baseline until the end of the study (Figure 1a) . Compatibly with the early activation of coagulation, D-dimer levels also increased threefold during the conditioning phase and remained elevated after engraftment, illustrating enhanced fibrin turnover (Figure 1b) . Thrombin time uniformly decreased to its lowest levels early after transplantation, the median being 15 s (25th and 75th percentiles 14 and 16 s; P ¼ o0.001), normalizing after engraftment. Fibrinogen increased twofold early after transplantation (Figure 1c ). The evolution of PT and APTT was clinically irrelevant. The individual variation was sevenfold in F1 þ 2 and 36-fold in D-dimer, suggesting heterogenic clinical factors. Thus, coagulation was activated early during conditioning therapy with ensuing fibrin and its degradation, followed by an acute phase reaction, elevation of fibrinogen and continued coagulation activity.
Fibrinolytic system
Subsequent to coagulation activity, we defined the extent and activity of the fibrinolytic system by the circulating levels of tPA and PAI-1. The levels of tPA Ag increased after engraftment and stayed elevated to the end of the study (Figure 2a) . However, the tPA Act was already high during conditioning, but peaked early after transplantation, remaining upregulated after engraftment. Despite the elevated levels of tPA Ag, the activity of tPA declined by the end of the study (Figure 2b ). In contrast, the activity of PAI-1 diminished to its lowest levels early during conditioning therapy and remained generally low early after transplantation (Figure 2c ). Compatibly, during this time D-dimer increased, implying fibrin degradation (Figure 1b) . In all, the activity of tPA and its regulator PAI-1 depicted their maximal impact early after transplantation.
Clinical characteristics
Two patients had heterozygous FV Leiden mutation and one had 2 Glycoprotein I antibodies, the prevalence of thrombophilia being similar to the normal national population. Low-risk disease was more common in the sibling transplant recipients than in unrelated recipients, whereas high-risk disease was equal (NS; Table 1 ).
Compatibly with low-risk disease status in the sibling transplant recipients, BM was the main source of the graft. Throughout the study, the patterns of variables were not affected by age, gender or disease status (ANOVA; data not shown). However, at single time points, some differences were noted. First, early after transplantation, F1 þ 2 levels were higher in the older than in the younger patient group (40 years as a cutoff; Mann-Whitney U-test; Table 2 ). In addition, tPA Ag levels were higher in the older than in the younger patients after engraftment and remained high till the end of the study.
Donor type and the source of the stem cell graft
In general, thrombin generation between the recipients of unrelated or sibling transplants did not differ (ANOVA; data not shown), but before transplantation, F1 þ 2 levels were higher when the donor was unrelated (Mann-Whitney U-test; P ¼ 0.05; Table 3 ). Instead, D-dimer and fibrinogen associated with the donor type throughout the study, (ANOVA; P ¼ o0.001; Table 3 ): D-dimer levels were 5-fold higher in the unrelated donor recipients during conditioning. Fibrinogen levels were elevated after engraftment, remaining high in the unrelated donor recipients. The unrelated and sibling donor recipients did not differ in the activity patterns of fibrinolysis throughout the study (ANOVA; data not shown), except in the tPA Ag (P ¼ 0.018). Initially, during conditioning therapy, the tPA Ag was higher in the unrelated than in the sibling donor recipients, but after engraftment the opposite was true (Table 3) . Also, PAI-1 Act differed between the recipients of the different donor types, already being lower in the unrelated than in the sibling donor recipients at the beginning, after engraftment and at the end (MannWhitney U-test; Table 3 ).
The activity patterns of coagulation and fibrinolysis were similar regardless of the source of the graft (ANOVA; data not shown). However, at one time point early after transplantation, the source of the graft affected thrombin generation: F1 þ 2 levels were over twofold higher in the recipients of peripheral blood than in those of BM SCT (Mann-Whitney U-test; Table 4 ). Interestingly, the tPA Act levels were simultaneously lower in the recipients of peripheral blood SCT (Table 4) .
Associations between coagulation and fibrinolytic markers During the study, many significant correlations between the activities of coagulation and fibrinolysis implied a tight regulation between these systems in the allogeneic SCT setting. Three main associations prevailed between the F1 þ 2 levels and D-dimer levels (Spearman's rank correlation coefficients, range 0.56-0.78), the Ag levels of tPA and the activity of PAI-1 (r ¼ 0.51-0.52). The activities of tPA and PAI-1 correlated inversely throughout the study (r ¼ À0.55 to -0.69).
Development and characteristics of GVHD Altogether, eight patients developed acute GVHD grade I or II: four of the 11 (36%) recipients of an unrelated transplant and four of the 19 (21%) recipients of a sibling transplant. GVHD appeared earlier in the recipients of an unrelated donor graft than in those who received a sibling donor graft (median 13 days, range 11-68 days versus 45 days, 44-75 days after transplantation; NS).
Next, we wanted to evaluate the implications of coagulation and fibrinolytic activities in the appearance of GVHD. Indeed, the increased degree of thrombin generation, elevated fibrinogen levels and simultaneous inhibition of fibrinolysis early after transplantation (on day þ 10) were all associated with the development of GVHD. None of the 11 patients whose thrombin generation was the lowest early after transplantation (F1 þ 2 o0.7 nmol/L) developed GVHD (P ¼ 0.014; r ¼ 0.46; Figure 3a) . Also, at the PAI-1 Act below 3.0 IU/mL early after transplantation, only 2 of 18 patients developed GVHD and an association between this PAI-1 Act level on day þ 10 and later GVHD Table 4 Significant differences in the activities of coagulation and fibrinolysis between the recipients of PB SCT and BM SCT was observed (P ¼ 0.034, r ¼ 0.43). Similarly, thrombin times early after transplantation were associated with the development of GVHD (P ¼ 0.006; r ¼ 0.57; Figure 3b ). Finally, fibrinogen early after transplantation was associated with (P ¼ 0.038; r ¼ 0.51) GVHD (OR 1.9, 95% CI 1.1-3.2, P ¼ 0.023). None of the 12 patients with fibrinogen levels lower than 5.5 g/L early after transplantation developed GVHD (P ¼ 0.010; r ¼ 0.49; Figure 3c ).
In the patients with thrombophilia, the levels of F1 þ 2 were threefold higher (P ¼ o0.05) early after transplantation (median 2.40, 25th percentile 1.13 and 75th percentile 2.70 nmol/L) than in the patients without (median 0.76, 25th and 75th percentiles 0.60 and 1.33 nmol/L). Thrombophilia and GVHD were associated, as all three thrombophilia patients experienced GVHD (P ¼ 0.014, r ¼ 0.55). Altogether, the presence of thrombophilia, increased thrombin generation, high fibrinogen levels and increased PAI-1 activity early after transplantation (on day þ 10) were associated with the development of GVHD, suggesting an intimate interplay between enhanced coagulation, inhibited fibrinolysis and immunology of GVHD.
Non-relapse mortality
The general outcome of the patients was quite good as overall survival at 2 years was 77%. The general clinical factors were not associated with non-relapse mortality or GVHD (data not shown). Three non-relapse deaths at 7, 8 and 23 months after SCT ensued. The deaths were due to diffuse alveolar damage, GVHD-associated severe infection and severe GVHD of the gut. The deceased patients were all PBSC recipients and generated most of the thrombin early after transplantation. The levels of F1 þ 2 over 1.5 nmol/L, tPA Ag over 20 ng/mL, tPA Act under 1.5 IU/mL and PAI-1 Act over 10 IU/mL associated with non-relapse mortality (P ¼ 0.014, 0.007, 0.002, 0.020; and r ¼ 0.55, 0.80, 0.75 and 0.75, respectively).
Discussion
In this prospective pilot study, coagulation and fibrinolysis were serially assessed in 30 allogeneic SCT patients receiving myeloablative conditioning therapy. We attempted to evaluate the natural evolution in the activities of coagulation and fibrinolysis in connection with SCT and analysed the impact of clinical factors, including age, gender, disease status, donor type and source of graft. Measured with several markers, we noted enhanced coagulation activity occurring during the early phase of SCT in accordance with earlier reports. 21 As a natural recovery mechanism, fibrinolysis was activated subsequently and, intriguingly, the fibrinolytic system has been found to regulate haematopoietic regeneration. 22 An impaired balance between early coagulation activity and fibrinolysis seemed to be associated with the later development of GVHD. In practical terms, currently available laboratory markers such as fibrinogen, D-dimer and thrombin time showed changes after SCT, which were associated with clinical outcome.
Increased thrombin generation was closely correlated with both the early activation of fibrinolysis and inhibition of its regulators during conditioning therapy (see Figures  1a and 2b, c ). This appears to represent a physiologically relevant regulation mechanism of coagulation. In addition, wide individual variation was evident. The early signs of thrombin generation seemed more marked in the recipients of an unrelated than a sibling transplant. This relates to the use of ATG, which was included in the conditioning therapy in the unrelated transplants and causes non-overt DIC according to an earlier report. 23 Although the recipients of sibling transplants were given steroid prophylaxis early on, no major differences were observed between the two types of donors after SCT. Interestingly, early after transplantation, F1 þ 2 levels were twofold higher, but the activity of fibrinolysis was simultaneously weaker in the SCT recipients of peripheral blood than in those of BM. Instead, the D-dimer levels were increased twofold initially during conditioning in the peripheral blood SCT recipients. Early thrombin generation seems to consume fibrinolytic activity, although it would be needed with sustained thrombin activity. This imbalance is in accordance with the exposure to lipopolysaccharides or endotoxin, that is, enhanced fibrinolytic activity paradoxically precedes coagulation activity. 24 Early steps in GVHD involve damage and activation of host tissues by conditioning therapy, release of lipopolysaccharides and secretion of proinflammatory cytokines, 25 which likely activate coagulation. The conditioning therapy also activates plts, induces their microvesiculation and tissue factor generation by endothelial damage. 26 These mechanisms imply sustained thrombin generation and short thrombin time in our study. 27 We plan further studies on the plasma-borne amplification and feedback of thrombin, where the proinflammatory role of fibrin and microvesicles 28, 29 appear important. We characterized several early adaptive mechanisms regulating coagulation and fibrinolysis in association with the development of GVHD. However, our study population of 30 patients is too limited for the multivariate analysis of several associating factors and firm conclusions cannot be drawn. Early after transplantation, during the aplastic phase, there are several reasons for the occurrence of coagulation disturbances, that is, mucositis and infections. However, in our study, these factors did not seem to explain our findings (data not shown). Despite this limitation, the complexity of the transplantation process and clinical factors, early thrombin generation and regulation of fibrinolysis interrelated with later GVHD. These new findings identify markers that could predict the development of unwanted complications, as suggested by a recent review on vascular endothelium and GVHD. 7 We have screened several related plasma markers to cover the crucial links between blood coagulation and fibrinolysis in allogeneic SCT. We conclude that conditioning therapy induces the early generation of thrombin, but compatible activation of fibrinolysis provides a favourable adaptation to SCT. The majority of the patients with modest thrombin generation and low PAI-1 Act early after transplantation managed without developing GVHD.
Although only three patients died after transplantation, early increased thrombin generation and low activity of fibrinolysis with its enhanced inhibition seemed to correlate with non-relapse mortality. On account of the limited size of our study, the possible associations between coagulation and GVHD need to be verified in a larger multicentre series allowing multivariate analysis to screen and develop preventive strategies. At least the most significant and feasible laboratory markers, thrombin time, fibrinogen and D-dimer, can be cost-efficiently evaluated in larger patient series to illustrate their clinical impact.
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